Log in with your email address username.


[Comment] Agonism of receptors in the gut–pancreas axis in type 2 diabetes: are two better than one?

Pharmacotherapy for type 2 diabetes has become complex with the advent of a large number of treatment options. Major goals of therapy include achieving glycaemic targets (glycated haemoglobin [HbA1c] ≤7%) to minimise the development and progression of microvascular and, to a lesser extent, macrovascular complications, while avoiding hypoglycaemia.1 Obesity is a key risk factor of type 2 diabetes—hence, the terminology diabesity.2 Weight loss, even when modest, might improve not only glycaemic control and cardiovascular risk but also hepatic steatosis—the non-alcoholic fatty liver disease that is now the most common cause of chronic liver disease globally.